Mölnlycke and Ondine Partner to Combat Healthcare-Associated Infections

Mölnlycke Health Care and Ondine Biomedical Inc. have announced a strategic partnership to distribute Ondine's Steriwave® nasal decolonization technology across the UK, Europe, and the Middle East. This collaboration aims to tackle healthcare-associated infections (HAIs) and antimicrobial resistance (AMR).

Steriwave is a light-activated nasal therapy that reduces harmful pathogens in the nasal passages without generating AMR. Clinically proven, it is already implemented in several NHS Trusts in the UK. Mölnlycke will leverage its extensive market presence to accelerate Steriwave's adoption.

The UK, with over three million major surgeries annually, will be the initial market focus in Q4 2024, followed by expansion into the EU and Middle East in 2025. Mölnlycke will integrate Steriwave into its infection control portfolio, enhancing its offerings in HAIs prevention and AMR reduction.

Key executives from both companies expressed excitement about the partnership, highlighting the potential to revolutionize patient care and sustainable healthcare practices globally.